We have demonstrated that PEPFAR-supported scale up of antiretroviral therapy (ART) was associated with reductions in HIV incidence, and large increases in life expectancy. Nevertheless, the rate of new HIV infections remains amongst the highest in the world (incidence in young women in the Africa Centre for Population Health area exceed 5% per year). These infections are characterised by major spatial heterogeneity, reflected in local “hotspots” (see Figure 1). In addition there remain major deficits in testing, linkage and retention in care.

What we’ll do

Our research will focus on reducing new infections, and optimising the treatment and care of those on antiretroviral therapy. We will quantify the impact that current interventions are having and we will identify optimal future prevention strategies.

Our key research questions:

  1. HIV Transmission Dynamics. What are the drivers of the epidemic?
  2. What are the optimal approaches to preventing HIV transmission?
  3. How to minimise morbidity and mortality in HIV infected individuals?
Figure 1: Proportion of the entire surveillance population having a detectable HIV-1 RNA viral load